196 related articles for article (PubMed ID: 33378977)
21. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of cordycepin in the treatment of pulmonary arterial hypertension in rats based on metabonomics and transcriptomics.
Lin J; Chen R; Liao H; Zhang Y; Zheng Z; Hong C
Sci Rep; 2024 May; 14(1):12431. PubMed ID: 38816406
[TBL] [Abstract][Full Text] [Related]
23. eIF2α promotes vascular remodeling via autophagy in monocrotaline-induced pulmonary arterial hypertension rats.
Guo L; Li Y; Tian Y; Gong S; Chen X; Peng T; Wang A; Jiang Z
Drug Des Devel Ther; 2019; 13():2799-2809. PubMed ID: 31496656
[TBL] [Abstract][Full Text] [Related]
24. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
25. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
[TBL] [Abstract][Full Text] [Related]
27. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Wang Q; Shi W; Zhang Q; Feng W; Wang J; Zhai C; Yan X; Li M
Life Sci; 2020 Feb; 242():117159. PubMed ID: 31837334
[TBL] [Abstract][Full Text] [Related]
29. Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension.
Zhang LL; Lu J; Li MT; Wang Q; Zeng XF
Int J Rheum Dis; 2016 Feb; 19(2):192-8. PubMed ID: 24612527
[TBL] [Abstract][Full Text] [Related]
30. Srolo Bzhtang reduces inflammation and vascular remodeling via suppression of the MAPK/NF-κB signaling pathway in rats with pulmonary arterial hypertension.
Chen T; Su S; Yang Z; Zhang D; Li Z; Lu D
J Ethnopharmacol; 2022 Oct; 297():115572. PubMed ID: 35872290
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension.
Huang WC; Ke MW; Cheng CC; Chiou SH; Wann SR; Shu CW; Chiou KR; Tseng CJ; Pan HW; Mar GY; Liu CP
PLoS One; 2016; 11(2):e0142476. PubMed ID: 26840075
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
[TBL] [Abstract][Full Text] [Related]
34. Protective effect of baicalin against pulmonary arterial hypertension vascular remodeling through regulation of TNF-α signaling pathway.
Xue X; Zhang S; Jiang W; Wang J; Xin Q; Sun C; Li K; Qi T; Luan Y
Pharmacol Res Perspect; 2021 Feb; 9(1):e00703. PubMed ID: 33421306
[TBL] [Abstract][Full Text] [Related]
35. Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling.
Fu J; Chen YF; Zhao X; Creighton JR; Guo Y; Hage FG; Oparil S; Xing DD
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1539-47. PubMed ID: 24790141
[TBL] [Abstract][Full Text] [Related]
36. Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.
Li H; Lu W; Cai WW; Wang PJ; Zhang N; Yu CP; Wang DL; Liu BC; Sun W
Pulm Pharmacol Ther; 2014 Jun; 28(1):17-24. PubMed ID: 24269521
[TBL] [Abstract][Full Text] [Related]
37. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
[TBL] [Abstract][Full Text] [Related]
38. Xbp1s-Ddit3 promotes MCT-induced pulmonary hypertension.
Jiang H; Ding D; He Y; Li X; Xu Y; Liu X
Clin Sci (Lond); 2021 Nov; 135(21):2467-2481. PubMed ID: 34676402
[TBL] [Abstract][Full Text] [Related]
39. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
40. Dihydroartemisinin Attenuates Pulmonary Hypertension Through Inhibition of Pulmonary Vascular Remodeling in Rats.
Tang M; Wang R; Feng P; Dong Q; Chen W; Zhao Y; Li A; Li H; Chen J; Huang W
J Cardiovasc Pharmacol; 2020 Sep; 76(3):337-348. PubMed ID: 32569012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
